TA5K, Psykiatrian yhteiset palvelut

Keyphrases

1. Hippocampal Sclerosis 100%
2. Drug-resistant Temporal Lobe Epilepsy 100%
3. Health Registries 54%
4. Dry Mouth 50%
5. Celiac Disease 50%
6. ErbB4 50%
7. Heavy Alcohol Use 50%
8. Depression Treatment 50%
9. Interleukin-6 Levels 50%
10. Intimate Partner Violence 50%
11. Polymorphism 50%
12. Health Registers 50%
13. Short-term Response 50%
14. Tachykinin Receptor 1 50%
15. Health-related Costs 50%
16. Alcohol Use Disorder 50%
17. Disease Pattern 50%
18. Clozapine 50%
19. Temporal Lobe Epilepsy 50%
20. Comparing Methods 50%
21. Mental Disorders 50%
22. Length of Hospital Stay 50%
23. Register-based 50%
24. Sialorrhea 38%
25. Temporal Lobe Epilepsy with Hippocampal Sclerosis 37%
26. Depression Study 33%
27. IL-6 Level 33%
28. Inpatient Episodes 33%
29. Number of Individuals 33%
30. Schizophrenia Spectrum Disorders 33%
31. Antipsychotics 30%
32. Response to Treatment 25%
33. Anti-gliadin Antibodies 21%
34. Behavioral Activation 16%
35. IL-6/IL-10 16%
36. Severe Depression 16%
37. Patients with Depression 16%
38. Motivational Interviewing 16%
39. Dual Pathology 16%
40. Alcohol 16%
41. Response Predictors 16%
42. Data Preprocessing 16%
43. Discharge Diagnosis 16%
44. Inpatient Care 16%
45. Number of Treatment 16%
46. Process Data 16%
47. Lifetime Diagnosis 16%
48. Non-processed 16%
49. Organic Mental Disorders 16%
50. Medical Contact 16%
51. R Script 16%
52. Lifetime Incidence 16%
53. Open Source R 16%
54. Preliminary Diagnosis 16%
55. Register Data 16%
56. Primary Care 16%
57. Outpatient Care 16%
58. Positive Groups 15%
59. Logistic Regression Model 13%
60. Health Care Costs 13%
61. Antibody-negative 12%
62. Valproate 11%
63. Norclozapine 11%
64. Interleukin-6 11%
65. Dryness 11%
66. Drug-resistant Epilepsy 9%
67. Data-centric 9%
68. Police Reports 9%
69. Attributable Cost 9%
70. Left Lateral Sectionectomy 8%
71. Substance Use 8%
72. Naturalistic Setting 8%
73. Trial Registration 8%
74. Treatment Options 8%
75. Specialty Care 8%
76. Psychosocial Intervention 8%
77. Treatment Response 8%
78. Beck Depression inventory-II (BDI-II) 8%
79. Depressive Symptoms 8%
80. Alcohol Use Disorders Identification Test (AUDIT) 8%
81. Treatment Interventions 8%
82. Positive Responses 8%
83. Comorbid Depression 8%
84. Evidence-based Methods 8%
85. Comorbid 8%
86. Severe Symptoms 8%
87. Symptom Severity 8%
88. Use of Evidence 8%
89. Systematic Use 8%
90. Comorbid Disorders 8%
91. Gluten Sensitivity 6%
92. Epilepsy Patients 6%
93. Cytokine Activation 5%
94. Drug-resistant Focal Epilepsy 5%
95. Serum Levels 5%
96. Right-sided 5%
97. Genetic Variation 5%
98. Epidermal Growth Factor Receptor 5%
99. Idiopathic Generalized Epilepsy 5%
100. Cytokine IL-6 5%